These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15473294)

  • 1. Selective COX-2 inhibitors should be used judiciously in the presence of renal impairment.
    Bhowmik D; Tiwari SC
    J Indian Med Assoc; 2004 Apr; 102(4):225. PubMed ID: 15473294
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cyclooxygenase inhibitors: adverse drug reactions are unavoidable, but only a few are (acutely) dangerous].
    Brune K; Renner B; Maas R
    Dtsch Med Wochenschr; 2009 Sep; 134(36):1771-3. PubMed ID: 19718601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular risks of selective COX-2-inhibitors].
    Schrör K
    Dtsch Med Wochenschr; 2004 Dec; 129(49):2653-6. PubMed ID: 15578320
    [No Abstract]   [Full Text] [Related]  

  • 4. [Selective COX-2 inhibitors and cardiovascular risk].
    Meier P; Meyer zu Straten A; Burnier M
    Rev Med Suisse; 2005 Feb; 1(8):543-6, 549-50. PubMed ID: 15794303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Selective COX-2 inhibitors--side effects in relation to non-specific non-steroidal anti-inflammatory drugs].
    Hansen JM; de Muckadell OB
    Ugeskr Laeger; 2004 Dec; 166(50):4581-4. PubMed ID: 15633545
    [No Abstract]   [Full Text] [Related]  

  • 6. Transient renal failure in twins with maternal Cox-1/Cox-2 use in pregnancy.
    Ali I; Ryan CA
    Ir Med J; 2005; 98(10):249-50. PubMed ID: 16445149
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
    Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
    Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative Cox inhibitors and late prosthetic loosening--suspicion increases!
    Aspenberg P
    Acta Orthop; 2005 Dec; 76(6):733-4. PubMed ID: 16470422
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
    Giannitsis E
    Clin Lab; 2005; 51(1-2):63-83. PubMed ID: 15719708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is there a future for COX-2 inhibitors?].
    Yodfat Y
    Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
    Mahajan A; Sharma R
    J Assoc Physicians India; 2005 Mar; 53():200-4. PubMed ID: 15926604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COX 2 selective inhibitors: what the newspapers have not told you.
    Simon LS
    Bull NYU Hosp Jt Dis; 2007; 65(3):229-41. PubMed ID: 17922675
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib].
    Ortiz M; Mon C; Fernández MJ; Sánchez R; Mampaso F; Alvarez Ude F
    Nefrologia; 2005; 25(1):39-43. PubMed ID: 15789535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [COX 2 inhibitors--a further step back].
    Slørdal L; Evensen S; Spigset O
    Tidsskr Nor Laegeforen; 2005 Apr; 125(8):1046. PubMed ID: 15852094
    [No Abstract]   [Full Text] [Related]  

  • 17. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
    Bannwarth B
    Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948
    [No Abstract]   [Full Text] [Related]  

  • 18. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
    Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S
    Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?
    Das UN
    J Assoc Physicians India; 2005 Jul; 53():623-7. PubMed ID: 16190133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.